Acta Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.

Science Translational Medicine is a premier journal published by the American Association for the Advancement of Science, dedicated to bridging the gap between laboratory discovery and clinical application. With an impressive impact factor and a Q1 categorization in the field of Medicine, it is recognized as one of the leading journals, ranking 11 out of 636 in general medicine according to Scopus, placing it in the top 2% of its category. Since its inception in 2009, the journal has been at the forefront of innovative research, presenting high-quality studies that translate scientific advancements into tangible medical solutions. Researchers, professionals, and students alike will find its rich content invaluable for staying informed on cutting-edge developments in the field. The journal's commitment to accessibility ensures that the latest findings and insights are available to a global audience, fostering collaboration and scientific progress.

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

Biomedical Research and Therapy is a pioneering journal published by BIOMEDPRESS, dedicated to the field of biomedical sciences. With its ISSN 2198-4093, this journal aims to disseminate high-quality research and innovative therapies that advance knowledge in biomedical research. Although it operates on a non-open access model, it provides crucial insights into various topics such as drug discovery, disease mechanisms, regenerative medicine, and clinical applications. The journal's rigorous peer-review process ensures the publication of critical findings and methodologies, making it a vital resource for researchers, practitioners, and students interested in the constantly evolving landscape of biomedical research. With converged years from 2020 to 2024 and an emerging reputation in its field, Biomedical Research and Therapy is positioned to contribute significantly to the global scientific community, enriching the discourse around therapeutic advancements and biomedical innovations.

The International Journal of Inflammation, published by HINDAWI LTD, serves as a vital resource within the field of Immunology and Allergy. With an established Open Access policy since 2010, this journal provides unrestricted access to cutting-edge research, fostering collaboration and dissemination of knowledge among researchers, professionals, and students. The journal’s ISSN is 2090-8040 and E-ISSN 2042-0099. Situated in the United States with administrative offices in England, it has consistently contributed to the academic community, evidenced by its ranking in the Q3 category for 2023, reflecting its significant presence in the field. Covering a wide range of topics from the molecular basis of inflammation to clinical implications and treatment strategies, the journal engages with the latest developments and current debates. With a Scopus rank of 145 out of 233 in the category of Medicine, its percentile rank of 37th indicates its influence and relevance in contemporary research. As the journal continues to evolve from its convergence years spanning from 2012 to 2024, it remains committed to advancing knowledge and innovation in inflammation research.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.